Charles River Laboratories International, Inc. (CRL) P/E Ratio History
Historical price-to-earnings valuation from 2001 to 2024
Loading P/E history...
CRL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Charles River Laboratories International, Inc. (CRL) trades at a price-to-earnings ratio of -62.5x, with a stock price of $181.94 and trailing twelve-month earnings per share of $-3.77.
The current P/E is 168% below its 5-year average of 91.5x. Over the past five years, CRL's P/E has ranged from a low of 20.9x to a high of 1230.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CRL trades at a 380% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CRL trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $30B | 22.8 | 0.56Best | +5% | |
| $12B | 28.1 | 0.88 | +21% | |
| $10B | 13.1Lowest | 1.87 | +29%Best | |
| $1B | 24.9 | - | -4% | |
| $5B | 35.6 | - | -52% | |
| $21B | 24.7 | - | +18% | |
| $8B | 25.5 | 1.11 | -25% | |
| $176B | 26.8 | 12.67 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CRL Historical P/E Data (2001–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $184.60 | $0.15 | 1230.7x | +1470% | |
| FY2024 Q3 | Sat Sep 28 2024 00:00:00 GM | $198.31 | $7.99 | 24.8x | -68% |
| FY2024 Q2 | Sat Jun 29 2024 00:00:00 GM | $206.58 | $8.35 | 24.7x | -68% |
| FY2024 Q1 | Sat Mar 30 2024 00:00:00 GM | $270.95 | $8.50 | 31.9x | -59% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $236.40 | $9.21 | 25.7x | -67% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $195.98 | $9.24 | 21.2x | -73% |
| FY2023 Q2 | Sat Jul 01 2023 00:00:00 GM | $210.25 | $9.43 | 22.3x | -72% |
| FY2023 Q1 | Sat Apr 01 2023 00:00:00 GM | $201.82 | $9.67 | 20.9x | -73% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $217.90 | $9.47 | 23.0x | -71% |
| FY2022 Q3 | Sat Sep 24 2022 00:00:00 GM | $187.51 | $8.49 | 22.1x | -72% |
| FY2022 Q2 | Sat Jun 25 2022 00:00:00 GM | $226.32 | $8.62 | 26.3x | -67% |
| FY2022 Q1 | Sat Mar 26 2022 00:00:00 GM | $279.10 | $8.21 | 34.0x | -57% |
Average P/E for displayed period: 78.4x
See CRL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRL — Frequently Asked Questions
Quick answers to the most common questions about buying CRL stock.
Is CRL stock overvalued or undervalued?
CRL trades at -62.5x P/E, below its 5-year average of 91.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CRL's valuation compare to peers?
Charles River Laboratories International, Inc. P/E of -62.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CRL's PEG ratio?
CRL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2001-2024.